Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer

Christian H Bergsland,1,2,3 Jarle Bruun,1,2 Marianne G Guren,2,4 Aud Svidland,2,3 Merete Bjorneslett,1,2 Jorgen Smeby,1,2,4 Merete Hektoen,1,2 Matthias Kolberg,1 Enric Domingo,5 Teijo Pellinen,2,6 Ian Tomlinson,7 David Kerr,9 David N Church,9,10,11 Arild Nesbakken,2,3,12 Anita Sveen,1,2,3 Ragnhild A Lothe1,2,3

ABSTRACT

Background There is a need for improved selection of patients for adjuvant chemotherapy after resection of non-metastatic colorectal cancer (CRC). Regulator of chromosome condensation 2 (RCC2) is a potential prognostic biomarker. We report on the establishment of a robust protocol for RCC2 expression analysis and prognostic tumour biomarker evaluation in patients who did and did not receive adjuvant chemotherapy.

Materials and methods RCC2 was analysed in 2916 primary CRCs from the QUASAR2 randomised trial and two single-hospital Norwegian series. A new protocol using fluorescent antibody staining and digital image analysis was optimised. Biomarker value for 5-year relapse-free survival was analysed in relation to tumour stage, adjuvant chemotherapy and the molecular markers microsatellite instability, KRAS/BRAFV600E/TP53 mutations and CDX2 expression.

Results Low RCC2 expression was scored in 41% of 2696 evaluable samples. Among patients with stage I–III CRC who had not received adjuvant chemotherapy, low RCC2 expression was an independent marker of inferior 5-year relapse-free survival in multivariable Cox models including clinicopathological factors and molecular markers (HR 1.45, 95% CI 1.09 to 1.94, p=0.012, N=521). RCC2 was not prognostic in patients who had received adjuvant chemotherapy, neither in QUASAR2 nor the pooled Norwegian series. The interaction between RCC2 and adjuvant chemotherapy for prediction of patient outcome was significant in stage III, and strongest among patients with microsatellite stable tumours (pInteraction=0.028).

Conclusions Low expression of RCC2 is a biomarker for poor prognosis in patients with stage I–III CRC and seems to be a predictive biomarker for effect of adjuvant chemotherapy.

INTRODUCTION

Colorectal cancer (CRC) is a global health challenge with more than 850 000 registered deaths each year.1 The management of patients with non-metastatic CRC after surgery of the primary tumour is primarily determined by cancer stage (tumour node metastasis (TNM) system), location and tolerability to chemotherapy.2 However, more than half of the patients with stage II and III colon cancer receiving adjuvant chemotherapy are cured by surgery alone, while some relapse after adjuvant chemotherapy, illustrating that current patient selection criteria for adjuvant chemotherapy results in substantial overtreatment and undertreatment.3 Molecular
profiling has no impact on adjuvant treatment protocols in stage III, while the microsatellite instability (MSI) hypermutator phenotype identifies a low-risk subgroup of patients with no predicted benefit from fluoropyrimidine chemotherapy in stage II.4

Several molecular tumour markers in addition to MSI status have been proposed to improve the risk stratification of primary CRCs. Among the most thoroughly investigated markers are BRAFV600E and KRAS mutations,5 and combined analysis of MSI, KRAS and BRAFV600E improves the prognostic assessment of stage II/III colon cancers, although only modestly when detailed clinicopathological data are included.6 Markers of infiltrating non-malignant cells in the tumour microenvironment may have a stronger prognostic potential than the cancerspecific genetic markers.7 A prominent stromal component indicates a poor patient survival, while infiltrating lymphocytes are associated with a favourable outcome.8 9 The Immunoscore, which is an immunohistochemistry (IHC) -based assay for profiling of tumour-infiltrating CD3+/total T-cells and CD8+/cytotoxic T-cells, improves the prognostic predictive power over clinicopathological factors alone.9 This has prompted development of a TNM-immune-based risk classification for adjuvant treatment decisions, and a recent study of stage III colon cancer patients reported a benefit of 6 months vs 3 months treatment with mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) in Immunoscore intermediate/high patients, which was not found in Immunoscore low patients.10 Of cancer cell-intrinsic markers, the strongest associations with benefit from adjuvant chemotherapy in stage III CRC have been presented for loss of CDX2 expression, although additional supporting data are needed to justify clinical use.11 12

Regulator of chromosome condensation 2 (RCC2) was originally identified as a 60kDa protein in a structure termed the ‘Telophase Disc’ (RCC2 is also known as TD-60).13 Functionally, RCC2 is important for proper functioning of the chromosomal passenger complex, which regulates key aspects of mitosis.14 Additionally, RCC2 has been shown to be involved in regulation of directional cell migration through its interaction with RAC1.15 In recent years, several studies have linked RCC2 to cancer progression,16-18 and we have reported that loss of RCC2 expression was associated with a poor prognosis in patients with primary CRC.18 Recently, RCC2 has been shown to be under transcriptional regulation by wild-type TP53 and loss of RCC2 in colon cancer cells was found to promote metastasis in an in vivo mouse model.19 RCC2 has also been associated with chemotherapy resistance in preclinical cancer models.17 21

In this study, we established a robust and accurate protocol for in situ analysis of RCC2 protein expression based on fluorescent IHC using a validated monoclonal antibody. We also investigated the value of RCC2 as a biomarker for prediction of patient outcome in relation to adjuvant chemotherapy in early stage CRC.

MATERIALS AND METHODS

This study is reported according to the Reporting recommendations for tumor marker prognostic studies (REMARK) (online supplemental table 1).22

Clinical samples and molecular data

Two independent Norwegian series of primary CRCs (total N=1720) and a British clinical trial series (QUASAR2, N=1196) were analysed (table 1 and online supplemental table 2). Norwegian series 1 (N=922) and 2 (N=798) were two single-hospital series of patients with stage I–IV primary CRCs treated by major surgical resection at Oslo University Hospital in the time periods 1993–2003 and 2003–2012, respectively. The series are population representative for the Southeast of Norway and adjuvant chemotherapy was administered according to national guidelines. Adjuvant chemotherapy has since 1997 been part of standard guidelines for stage III and now also for high-risk stage II colon cancer patients younger than 76 years. This explains why only 58 out of 223 R0-resected stage III patients in the first series (1993–2003) received chemotherapy (table 1 and further details in online supplemental table 2). For patients in the second Norwegian series (2003–2012), adjuvant chemotherapy was given as standard for stage III colon cancer, but on a case-by-case basis according to tolerability in patients above 75 years (6 out of 56 R0-resected stage III colon cancer patients above 75 received). Adjuvant chemotherapy was also administered according to risk assessments in patients with rectal cancer (7 out of 113 R0-resected stage III rectal cancer patients received across the two cohorts). Five-year follow-up for cancer recurrence and survival was complete for all patients except two (one censored at 4.2 years and one with missing information). QUASAR2 was an international, multicentre, phase 3, randomised clinical trial, enrolling 1952 stage III and high-risk stage II CRC patients in the time period 2005–2010.23 These patients were randomly assigned to receive capecitabine alone or capecitabine to risk assessments in patients with rectal cancer (7 out of 113 R0-resected stage III rectal cancer patients received together with bevacizumab in the adjuvant setting.

Construction of tissue microarrays (TMAs) and molecular analyses in the QUASAR2 cohort were performed as previously reported.24–25 Patients from QUASAR2 were included in this study based on availability of TMAs and clinical data.

For the Norwegian series 1, MSI-status and KRAS- and BRAFV600E-mutational status have been published.26 TMAs with 0.6mm diameter cores were built from formalin-fixed paraffin-embedded (FFPE) tumour tissue,10 and CDX2 expression has been published elsewhere.12 For the Norwegian series 2, MSI status, KRAS, BRAFV600E and TP53 mutational status, as well as CDX2-expression were also previously reported and available for major subsets of the samples (see table 1).12 26 27 TMAs were constructed with 1.0mm diameter cores from FFPE blocks, similarly to the Norwegian series 1. Deficient mismatch repair status was additionally determined by IHC for the mismatch repair proteins MLH1 (MutL homolog 1), MSH2 (MutS
| Table 1     | Clinicopathological characteristics of the three CRC cohorts                                      |
|------------|-------------------------------------------------------------------------------------------------|
|            | Single-hospital series (consecutive)  | Norwegian series 1  | Norwegian series 2  | P value | QUASAR2 (2005–2010) |
|            |                                   | (1993–2003)  | (2003–2012)  |        |                     |
| Total patients, N |                                   | 922  | 798  |        | 1196   |
| Age        |                                   | 73 (29–94) | 72 (27–97) | 0.60 | 65 (21–85)        |
| Sex        |                                   | 485 (53%) | 407 (51%) | 0.53 | 507 (42%)        |
|           | Female                             | 437 (47%) | 391 (49%) |        | 689 (58%)        |
| TNM stage  |                                   | 137 (15%) | 167 (21%) | 0.007 | –                 |
| I          |                                   | 381 (41%) | 288 (36%) | 0.007 | –                 |
| II         |                                   | 242 (26%) | 214 (27%) | 0.007 | –                 |
| III        |                                   | 159 (17%) | 129 (16%) | 0.007 | –                 |
| NA         |                                   | 3         | –         |        | –                 |
| Resection status |                                   | 719 (78%) | 651 (82%) | 0.09 | 1196 (100%)      |
| R0         |                                   | 36 (4%)   | 19 (2%)   | 0.09 | –                 |
| R1         |                                   | 167 (18%) | 128 (16%) | 0.09 | –                 |
| Tumour location        |                                   | 365 (40%) | 327 (41%) | 0.29 | 445 (42%)     |
| Right colon |                                   | 301 (33%) | 239 (30%) | 0.29 | 490 (46%)     |
| Left colon  |                                   | 231 (25%) | 218 (27%) | 0.29 | 132 (12%)     |
| Rectum     |                                   | 25 (3%)   | 14 (2%)   | 0.29 | –                 |
| Synchronous |                                   | 129       | –         | 129   | –                 |
| NA         |                                   | –         | –         | –     | 129   |
| MSI        |                                   | 128 (15%) | 120 (16%) | 0.78 | 154 (13%)     |
| MSS        |                                   | 712 (85%) | 638 (84%) | 0.78 | 988 (87%)     |
| NA         |                                   | 82        | 40        | –     | 54           |
| BRAFV600E mutational status |                                   | 650 (85%) | 288 (83%) | 0.66 | 956 (87%)     |
| Wild-type  |                                   | 119 (15%) | 57 (17%)  | 0.66 | 142 (13%)    |
| Mutated    |                                   | 153       | 453       | 0.66 | 98       |
| NA         |                                   | –         | –         | –     | –             |
| KRAS mutational status |                                   | 463 (69%) | 238 (69%) | 0.94 | –             |
| Wild-type  |                                   | 204 (31%) | 106 (31%) | 0.94 | –             |
| Mutated    |                                   | 255       | 454       | 0.94 | –             |
| NA         |                                   | –         | –         | –     | –             |
| CDX2 expression status |                                   | 568 (89%) | 281 (89%) | 0.91 | –             |
| Positive   |                                   | 71 (11%)  | 34 (11%)  | 0.91 | –             |
| Negative   |                                   | –         | –         | –     | –             |
| NA         |                                   | 283       | 483       | –     | –             |
| TP53 mutational status |                                   | –         | –         | –     | –             |
| Wild-type  |                                   | 145 (42%) | –         | –     | –             |
| Mutated    |                                   | 202 (58%) | –         | –     | –             |
| NA         |                                   | –         | 451       | –     | –             |
| RCC2 score, continuous |                                   | –         | –         | –     | –             |

Continued
Individual patient data cannot be shared.

Procedures
Two procedures for IHC-based analyses of cytoplasmic RCC2 expression were used. Norwegian series 1 has previously been analysed for nuclear and cytoplasmic expression using a standard DAB (3,3'-Diaminobenzidine)-based chromogenic protocol and a polyclonal antibody, combined with manual scoring of RCC2 staining by the Allred method, providing eight categories of RCC2 expression based on staining proportion and intensity. The same protocol was here used for analysis of the QUASAR2 trial cohort (details in online supplemental methods). Samples with a cytoplasmic Allred score <5 were scored as having low expression of RCC2. Further, we developed a new protocol for scoring RCC2 expression, based on a monoclonal antibody against RCC2, fluorescent staining and digital image analysis by applying the Vectra 3 Imaging platform and Inform analysis software (Akoya Biosciences) (online supplemental methods). This method was technically validated on the Norwegian series 1, and then used to analyse the Norwegian series 2. With this new protocol, both cytoplasmic and nuclear expressions of RCC2 were scored. The fluorescence protocol provided continuous data for RCC2 expression, and the threshold for dichotomisation into high and low expression groups was set to match the percentage of tumours in each category in our previous analysis of Norwegian series 1 with the chromogenic protocol (41st percentile). This was also in line with the percentage of samples in each category in the QUASAR2 cohort (40.3% scored into the low RCC2 category with an Allred score <5). Totally 2916 CRCs from the three patient series were analysed for RCC2 expression, and 2696 (92.5%) tumours were evaluable. Online supplemental figure 1 shows an overview of patient samples included in the main analyses, and online supplemental figure 2 shows an overview of the methodology applied to each cohort.

Table 1

| Table 1 | Continued |
|-----------------|-----------------|-----------------|
|                | Single-hospital series (consecutive) | Randomised clinical trial |
|                | Norwegian series 1 (1993–2003) | Norwegian series 2 (2003–2012) | P value | QUASAR2 (2005–2010) |
| median (IQR)   | −0.24 (1.06)*    | −0.31 (1.08)*    | §        | 5 (3)†                |
| RCC2 score, dichotomised |                   |                   |          |                      |
| RCC2 Low       | 353 (41%)        | 309 (41%)        | §        | 439 (40%)            |
| RCC2 High      | 500 (59%)        | 444 (59%)        |          | 651 (60%)            |
| NA             | 69               | 45               | 106      |                      |
| Adjuvant chemotherapy (in R0-rected stage III patients)‡ |                   |                   |          |                      |
| No             | 165 (74%)        | 109 (54%)        | <0.0001  | 0 (0%)               |
| Yes            | 58 (26%)         | 93 (46%)         |          | 1196 (100%)          |

P values were calculated to determine if there were any statistical differences between the two consecutive Norwegian series; Wilcoxon rank-sum test was used for age, Fisher’s exact test for sex, MSI, BRAF, KRAS, CDX2-status and chemotherapy and χ² test for TNM stage, resection status and tumour location.

*Scaled continuous score.
†Allred score.
‡Adjuvant chemotherapy for stage III CRC was introduced in national guidelines in 1997, and therefore, a lower proportion of patients in Norwegian series 1 received such treatment. Additional details are provided in online supplemental table 2.
§Statistical analysis not relevant since the continuous RCC2 scores were scaled within each series and dichotomisation was performed such that the proportions of RCC2 low/high patients matched previous analysis, as described in the Methods section.
CRC, colorectal cancer; MSI, microsatellite instable; MSS, microsatellite stable; NA, Not available; RCC2, Regulator of chromosome condensation 2; TNM, tumour node metastasis.

homolog 2), MSH6 (MutS homolog 6) and PMS2 (PMS1 homolog 2) in the Norwegian series 2 (online supplemental methods).
Kaplan-Meier survival curves were compared using the log-rank test. HRs and 95% CIs were estimated by univariable and multivariable Cox proportional hazards models. Covariates included in the multivariable model for patients with stage I–III CRC and who did not receive chemotherapy were based on clinical relevance, and also included relevant molecular variables, which are listed in Table 1 (TP53 mutational status was not included in the model due to a low proportion of samples with available TP53 data). A full model including all variables was evaluated and only patients with complete data for all variables were included in the analysis. Since a large proportion of samples in the Norwegian series 2 were missing data for proportion of samples in the Norwegian series 2 were all variables were included in the analysis. Since a large proportion of samples in the Norwegian series 2 were missing data for the model due to a low proportion of samples with available TP53 data. A full model including all variables was evaluated and only patients with complete data for all variables were included in the analysis. Since a large proportion of samples in the Norwegian series 2 were missing data for proportion of samples in the Norwegian series 1 (table supplemental). The only statistically significant differences between these two series with respect to patient characteristics was a somewhat higher proportion of stage I and a lower proportion of stage II in the Norwegian series 2 compared with 1, and that a higher proportion of patients received adjuvant chemotherapy in the Norwegian series 2 compared with 1 (table 1). This is explained by the fact that national guidelines were updated in 1997 (described above). Therefore, analyses of the association between RCC2, adjuvant chemotherapy and survival were also performed within each series individually (online supplemental material). Survival analyses in the Norwegian series were performed with RCC2 both as a dichotomised and as a continuous variable, and results from analyses of the continuous expression data are reported for all main models in online supplemental table 7. The Wald statistic was used to estimate the p value for continuous RCC2 scores and for the effects of individual variables in multivariable models. Testing of proportional hazards assumptions were performed with the cox.zph function in the survival package. The assumption of proportional hazards was met in all analyses, except for in univariable survival analysis of age, TNM stage and CDX2 expression, as indicated in table 2, and the multivariable model in online supplemental table 6. This model was therefore also evaluated on stratification by TNM stage and age, which gave similar results for the prognostic value of RCC2 (data not included). The survMisc package was used to calculate the relative proportion of explained variation in 5-year RFS by each variable included in multivariable analysis.29 Kaplan-Meier plots were generated using the survminer package (V.0.4.3). All statistical tests were two sided and p values <0.05 were considered significant. Bonferroni correction was used to account for multiple testing; subgroup analyses of RCC2 according to treatment with chemotherapy (including stratified analysis by MSI-status) and according to TP53 status were adjusted by a factor of 8, and are reported in the relevant figures.

RESULTS
Robust method for fluorescent IHC-based analysis of RCC2 expression
We implemented a new protocol for evaluation of in situ RCC2 protein expression on a continuous scale, based on fluorescent IHC staining. The protocol was found to be robust in Norwegian series 1 (figure 1A–D). First, specificity of the monoclonal antibody against RCC2 was confirmed in an HAP1 RCC2 knockout cell-line model (figure 1A). Second, RCC2 showed a varied nuclear and cytoplasmic staining pattern, with a large range of expression values (figure 1B). Third, fluorescence analyses of RCC2 expression using two different digital pathology solutions were concordant (Pearson’s r=0.90, figure 1C, described in online supplemental methods). Cytoplasmic and nuclear expression of RCC2 were correlated among tumours (Pearson’s r=0.77); however, cytoplasmic RCC2 staining was more strongly associated with patient outcome (online supplemental figure 4). This was in line with previous results,19 and all further analyses are therefore based on the cytoplasmic expression of RCC2. Importantly, the association between cytoplasmatic RCC2 and 5-year RFS among stage I–III patients was similar when compared with our previously published results from DAB-based visual scoring of RCC2 in this patient series (DAB-based visual: HR=1.51, p=0.0011; fluorescence-based digital: HR=1.56, p=0.0005; N=599, figure 1D).29 We further compared methodologies by association analyses with molecular variables (online supplemental table 3). There were no significant associations between RCC2 expression and KRAS mutations, BRAFV600E, mutations or CDX2 expression by either method. Low RCC2 expression was more frequently found in microsatellite stable (MSS) tumours, although this association was not significant by the new RCC2 scoring method with monoclonal antibody and digital analysis (p=0.06).

Low RCC2 expression is associated with advanced cancer stage
Totally 2696 CRCs were scored for RCC2 expression across the two Norwegian series and QUASAR2 (92.5% of the analysed samples, online supplemental figure 1). Of these, 1101 (41%) were scored with low RCC2 expression. A lower proportion of stage II in the Norwegian series 2 had a 5-year RFS of 64% compared with 58% in the Norwegian series 1 (online supplemental figure 3). The only statistically significant differences between these two series with respect to patient characteristics was a somewhat higher proportion of stage I and a lower proportion of stage II in the Norwegian series 2 compared with 1, and that a higher proportion of patients received adjuvant chemotherapy in the Norwegian series 2 compared with 1 (table 1). This is explained by the fact that national guidelines were updated in 1997 (described above). Therefore, analyses of the association between RCC2, adjuvant chemotherapy and survival were also performed within each series individually (online supplemental material). Survival analyses in the Norwegian series were performed with RCC2 both as a dichotomised and as a continuous variable, and results from analyses of the continuous expression data are reported for all main models in online supplemental table 7. The Wald statistic was used to estimate the p value for continuous RCC2 scores and for the effects of individual variables in multivariable models. Testing of proportional hazards assumptions were performed with the cox.zph function in the survival package. The assumption of proportional hazards was met in all analyses, except for in univariable survival analysis of age, TNM stage and CDX2 expression, as indicated in table 2, and the multivariable model in online supplemental table 6. This model was therefore also evaluated on stratification by TNM stage and age, which gave similar results for the prognostic value of RCC2 (data not included). The survMisc package was used to calculate the relative proportion of explained variation in 5-year RFS by each variable included in multivariable analysis.29 Kaplan-Meier plots were generated using the survminer package (V.0.4.3). All statistical tests were two sided and p values <0.05 were considered significant. Bonferroni correction was used to account for multiple testing; subgroup analyses of RCC2 according to treatment with chemotherapy (including stratified analysis by MSI-status) and according to TP53 status were adjusted by a factor of 8, and are reported in the relevant figures.
between the two adjuvant treatment groups in QUASAR2 (online supplemental table 5).

**Table 2** Univariable and multivariable 5-year relapse-free survival analyses in stage I–III chemotherapy untreated patients in the pooled Norwegian series

| Variable                  | Strata     | Patients, N | Univariable analysis | Multivariable analysis |
|---------------------------|------------|-------------|-----------------------|------------------------|
|                           |            |             | HR (95% CI)           | P value                |
|                           |            |             | N=521, events=201     |                         |
| RCC2                      | High       | 691         | 1                     |                         |
|                           |           | 426         | 1.54 (1.28 to 1.86)   | <0.0001                |
|                           | Low        |             |                       |                        |
| Sex                       | Female     | 620         | 1                     |                         |
|                           | Male       | 577         | 1.09 (0.91 to 1.30)   | 0.37                   |
| Age                       | Below median† | 520     | 1.83 (1.51 to 2.22)   | <0.0001*               |
|                           | Above or equal to median† | 677     |                       |                        |
| TNM stage                 | I          | 302         | 1                     |                         |
|                           | II         | 622         | 1.71 (1.32 to 2.21)   | <0.0001*               |
|                           | III        | 273         | 3.12 (2.37 to 4.10)   | <0.0001*               |
| Tumour location           | Right colon| 469         | 1                     |                         |
|                           | Left colon | 332         | 1.19 (0.96 to 1.49)   | 0.12                   |
|                           | Rectum     | 367         | 0.99 (0.79 to 1.24)   | 0.95                   |
|                           | Synchronous| 29          | 1.19 (0.66 to 2.14)   | 0.56                   |
| MSI status                | MSI        | 198         | 1                     |                         |
|                           | MSS        | 911         | 1.28 (0.99 to 1.67)   | 0.059                  |
| BRAF V600E mutational status | Wild-type | 652         | 1                     |                         |
|                           | Mutated    | 124         | 0.95 (0.69 to 1.30)   | 0.75                   |
| KRAF mutational status    | Wild-type  | 490         | 1                     |                         |
|                           | Mutated    | 209         | 1.22 (0.95 to 1.56)   | 0.13                   |
| CDX2 expression status    | Positive   | 610         | 1                     |                         |
|                           | Negative   | 68          | 1.22 (0.83 to 1.79)   | 0.31*                  |

Multivariable analysis was stratified by series.

*Violates proportional hazards assumption in univariable analysis.
†Above/below median age (73) of all patients in the pooled series.
MSI, microsatellite instable; MSS, microsatellite stable; RCC2, Regulator of chromosome condensation 2; TNM, tumour node metastasis.

**Low expression of RCC2 is associated with benefit from chemotherapy in stage III CRC**

Analysis of stage I–III patients in the independent Norwegian series 2 validated the prognostic value of low RCC2 expression for 5-year RFS (HR 1.50, 95% CI 1.16 to 1.95, log-rank p=0.002, N=607, figure 2A). However, there was no significant difference in the 5-year RFS rate according to RCC2 expression in the QUASAR2 cohort (HR 1.13, 95% CI 0.90 to 1.42, log-rank p=0.28, N=1090, figure 2B), irrespective of cancer stage (stage II or III, online supplemental figure 5) or treatment regimen (online supplemental figure 6). As all patients in QUASAR2 received adjuvant chemotherapy, and this was the case for only 9% and 16% of stage I–III CRCs in the Norwegian series 1 and 2, respectively (online supplemental table 2), we speculated that this discrepancy could be due to an interaction between RCC2 and chemotherapy. The two Norwegian series were pooled for further analyses, and this confirmed that RCC2 was not prognostic in the subgroup of patients who did receive adjuvant chemotherapy (HR 0.90, 95% CI 0.55 to 1.48, log-rank p=0.67, N=158, figure 2C), irrespective of the treatment type (online supplemental figure 7). In contrast, low expression of RCC2 was significantly associated with worse outcome among patients who did not receive chemotherapy (HR 1.54, 95% CI 1.28 to 1.86, log-rank p<0.0001, N=1117, figure 2C and online supplemental figure 8). A test for interaction in stage III patients showed that adjuvant chemotherapy was associated with higher 5-year RFS rate in patients with low RCC2 expression (p interaction=0.047, figure 3A,B and online supplemental figure 9). Stratification according to MSI status further showed that low expression of RCC2 was associated with benefit from chemotherapy only in the MSS subgroup (p interaction=0.028, figure 3C and online supplemental figure 10). Analyses excluding rectal cancer patients showed the same trend as when all patients were analysed together (online supplemental figures 11
and 12). Exploratory analyses suggested that the benefit from chemotherapy in the RCC2-low subgroup was independent of CDX2 expression, but the number of tumours with low CDX2 expression was too small to draw a firm conclusion (online supplemental figure 13).

Prognostic value of RCC2 is independent of clinicopathological and molecular markers in patients with no adjuvant treatment

The prognostic value of RCC2 among patients in the pooled Norwegian series who did not receive adjuvant chemotherapy was further analysed in a full multivariable
Figure 2 Five-year survival according to RCC2 status in stage I–III patients of the Norwegian series 2 (A), the QUASAR2 cohort (B), and in the pooled Norwegian series split by adjuvant chemotherapy (C). The relative proportion of explained variation in 5-year relapse-free survival for each clinicopathological and molecular variable in multivariable analysis of stage I–III CRC patients who did not receive adjuvant chemotherapy was calculated (D). CRC, colorectal cancer; MSI, microsatellite instability; RCC2, Regulator of chromosome condensation 2; TNM, tumour node metastasis.
Cox model including other molecular and clinicopathological parameters. RCC2 retained independent prognostic value in this model (HR 1.45, 95% CI 1.09 to 1.94, p=0.012, N=521, table 2). A model excluding KRAS, BRAFV600E and CDX2 as covariables allowed for inclusion of more patients and gave similar results for the prognostic value of RCC2 (online supplemental table 6). RCC2 was estimated to contribute 9.6% of the relative proportion of explained variation in 5-year RFS (figure 2D). Although clinicopathological factors contributed with the majority (71.3%) of explained variation (figure 2D), RCC2 had a stronger prognostic impact than any of the other molecular variables (≤8.1% of explained variation). The relatively low number of patients with known TP53 mutation status (a subset of the Norwegian series 2 only, N=347, table 1) precluded inclusion in multivariable analysis.

Figure 3  Low RCC2 is associated with benefit from chemotherapy in stage III patients of the pooled Norwegian series. Benefit of adjuvant chemotherapy was assessed in all stage III patients (A), according to low/high RCC2 (B) and according to low/high RCC2 in MSS patients only (C). MSS, microsatellite stable; RCC2, Regulator of chromosome condensation 2.
However, RCC2 was found to be significantly associated with patient outcome only in TP53 mutated (HR 2.58, 95% CI 1.34 to 4.95, p=0.0031, adj. p=0.025), not in TP53 wild-type tumours (HR 1.06, 95% CI 0.47 to 2.39, p=0.89, adj. p=1) (p_interaction=0.089, online supplemental figure 14).

**DISCUSSION**

Optimisation of adjuvant chemotherapy in stage II and III CRC is an ongoing debate, in particular for the subgroup of patients with MSS cancers. The decision to treat in this setting is currently based on tumour stage, colon or rectal cancer, prognostic factors and patient tolerability to treatment. Our results suggest that patients with stage III MSS CRC and low expression of the RCC2 protein may have superior benefit from adjuvant chemotherapy than patients with high RCC2 expression. We have previously reported that RCC2 is an independent prognostic biomarker in primary CRC (in Norwegian series 1). In the present study, this was validated in an independent series from the same hospital, but only in patients who did not receive adjuvant chemotherapy. There was a statistically significant interaction between RCC2 and chemotherapy for outcome in the combined Norwegian series, implying that a low expression of RCC2 was predictive of the effect of chemotherapy in this retrospective analysis of an observational study cohort treated according to national guidelines. In support of this predictive effect, preclinical studies of cell line models from ovarian, lung, cervical and breast cancer have demonstrated an association between high expression of RCC2 and resistance to chemotherapy.

We could only analyse interactions between RCC2 and chemotherapy in patients with stage III CRC, due to the low number of stage I and II patients who received such treatment. However, the association between low RCC2 expression and poor prognosis in chemotherapy-untreated cancers was strong also in stage II (online supplemental figure 15), suggesting a potential to improve the outcome of patients in the low-RCC2 subgroup also in this stage. In fact, RCC2 was found to be an independent prognostic biomarker in multivariable analysis of chemotherapy-untreated stage I–III patients, after adjusting for TNM stage, patient age, sex, tumour location, MSI status, CDX2 expression, BRAF\(^{V_{600}E}\), and KRAS mutation status. A limitation in this analysis was the missing information on the molecular variables CDX2, BRAF\(^{V_{600}E}\), and KRAS for a proportion of the patients. However, results for RCC2 analysed in a multivariable model excluding these variables, which allowed for inclusion of substantially more patients, were virtually identical. Furthermore, the association between RCC2 and benefit from chemotherapy was independent of treatment regimen, and the results were similar for 5-fluorouracil monotherapy or in combination with oxaliplatin. Loss of CDX2 expression has been proposed as a biomarker for benefit from chemotherapy in CRC, also in our patient cohorts. However, RCC2 seemed to be independent of CDX2 in this setting, but due to the low number of CDX2 negative cases, we cannot firmly conclude on the prognostic relationship between RCC2, CDX2 and adjuvant chemotherapy.

A study by Song et al has reported that wild-type TP53 may transcriptionally activate RCC2, which in turn inhibits RAC1 and thus prevents formation of metastases. Although these results are interesting, we did not find any differences in RCC2 expression levels related to TP53 mutational status. However, we did find low RCC2 expression to be associated with a poor patient prognosis only in TP53 mutated, and not in TP53 wild-type tumours. It is important to note that in our study we analysed cytoplasmic RCC2 expression, since this was found to be a stronger predictor of patient outcome than nuclear expression. It is possible that this relates to the interaction RCC2 has with RAC1 in the cytoplasm, in contrast to its role in the nucleus where RCC2 regulates the chromosomal passenger complex. However, the nuclear and cytoplasmic expressions of RCC2 were strongly correlated, and additional studies are needed to clarify the functional relationship between RCC2 and its biomarker value. Notably, high expression of RCC2 has been linked to epithelial-mesenchymal transition and worse outcome in other cancer types, including lung and breast cancer, suggesting that the effect of RCC2 might be cancer type-dependent.

In the current study, we developed and employed a new methodological approach for in situ analysis of RCC2 by IHC, including the use of a validated monoclonal antibody, which facilitates potential future use in the clinic. We used fluorescent staining and digital image analysis, which together offer continuous scoring of biomarkers, and increases throughput of TMA-analyses by eliminating the process of visual scoring. Considering the different scale of these continuous data compared with the categorised RCC2 expression data provided by DAB-staining and visual analysis by the Allred method, we did not perform benchmarking of the two methods. However, due to the large dynamic linear range and continuous scoring scale provided by the new method, this approach is well suited for accurate and objective biomarker analyses. In summary, we have shown that low expression of RCC2 is a biomarker for a poor prognosis in non-metastatic CRC, and our data suggest that it may also be a predictive marker for a survival benefit from adjuvant chemotherapy.

**Author affiliations**

1Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
2K.G. Jebsen Colorectal Cancer Research Centre, Clinic for Cancer Medicine, Oslo University Hospital, Oslo, Norway
3Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
4Department of Oncology, Oslo University Hospital, Oslo, Norway
5Department of Oncology, University of Oxford, Oxford, UK
6Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
Acknowledgements The authors are thankful for all help from Mette Fursund at the Department for Pathology at the Norwegian Radium Hospital, Oslo University Hospital.

Contributors Conception and design: JB and RAL. Development of methodology: CHB, JB, AS and TP. Acquisition of data: all authors. Analysis and interpretation of data: all authors. Drafting of manuscript: CHB, JB, AS, RAL. Revision and final approval of manuscript: all authors. Administrative, technical or material support: AN and RAL. Study supervision: RAL.

Funding This study was financially supported by the South-Eastern Norway Regional Health Authority (Project Number 2016123, supporting CHB with a PhD fellowship), by the foundation "Stiftelsen Kristian Gerhard Jebsen" supporting JB as a PhD fellow, by the Norwegian Cancer Society (Grant No. 182759-2016, 6824046-2016 and 190188-2017), the Research Council of Norway, in cooperation with the University of Oslo, through the ‘Toppforsk’ grant (Project Number 250993), and by the NIHR Biomedical Research Centre, Oxford, UK. ED is supported by the S:CORT consortium which is funded by a grant from the Medical Research Council and Cancer Research UK.

Disclaimer The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Competing interests The authors RAL, JB, MK and AN are co-inventors of a relevant patent grant (US2017038386).

Patient consent for publication Not required.

Ethics approval The study was approved by the Regional Committees for Medical and Health Research Ethics- REC South East Norway (project number 2005.1629), and a signed material transfer agreement was made between Oxford University (provider) and Oslo University Hospital (recipient) for analysis of the QUASAR2 material.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as online supplemental information. Individual patient data cannot be shared.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and any changes made are indicated. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iD Christian H Bergsland http://orcid.org/0000-0001-7700-8156

REFERENCES

1 Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.

2 Schmol HJ, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012;23:2479–516.

3 Gill S, Loprinzi CL, Sargent DJ, et al. Paired analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22:1797–806.

4 Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for clinical pathology, College of American pathologists, association for molecular pathology, and the American Society of clinical oncology. J Clin Oncol 2017;35:1453–86.

5 Taieb J, Zaana N, Le Mallicot K, et al. Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a charac-torisation analysis of the PETOR oncology trial. Ann Oncol 2016;27:443–53.

6 Dienstmann R, Mason MJ, Sinicrope FA, et al. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol 2017;28:1023–31.

7 Dienstmann R, Villacampa G, Sween A, et al. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. Ann Oncol 2019;30:1622–9.

8 Colan A, Lonardo E, Berenguer-Llrog A, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 2015;47:320–9.

9 Pagès F, Mlecnik B, Marlot F, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 2018;391:2128–39.

10 Pagès F, André T, Taieb J, et al. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. Ann Oncol 2020;31:921–9.

11 Dalerba P, Sahoo D, Paik S, et al. Cdx2 as a prognostic biomarker in stage II and stage III colon cancer. N Eng J Med 2016;374:211–22.

12 Bruun J, Sween A, Barros F, et al. Prognostic accuracy, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. Mol Oncol 2018;12:1639–55.

13 Andreassen PR, Palmer DK, Wener MH, et al. Telophase disc: a new mammalian mitotic organelle that bisects telophase cells with a possible function in cytokinesis. J Cell Sci 1991;99 (Pt 3):523–34.

14 Mollinari C, Reynaud C, Martinneau-Thullier S, et al. The mammalian passenger protein TD-60 is an RCC1 family member with an essential role in prometaphase to metaphase progression. Dev Cell 2005;3:295–307.

15 Humphries JD, Byron A, Bass MD, et al. Proteomic analysis of integrin-associated complexes identifies RCC2 as a dual regulator of Rac1 and ARF6. Sci Signal 2009;2:ra51.

16 Pang B, Wu N, Guan R, et al. Overexpression of RCC2 enhances cell motility and promotes tumour metastasis in lung adenocarcinoma by inducing epithelial-mesenchymal transition. Clin Cancer Res 2017;23:5598–610.

17 Wu N, Ren D, Li S, et al. RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation. BMC Cancer 2018;18:67.

18 Matsuo M, Nakada C, Tsukamoto Y, et al. Mir-29C is downregulated in gastric carcinomas and regulates cell proliferation by targeting RCC2. Mol Cancer 2013;12:15.

19 Bruun J, Kolberg M, Ahlquist TC, et al. Regulator of chromosome condensation 2 identifies high-risk patients with both major phenotypes of colorectal cancer. Clin Cancer Res 2015;21:3759–70.

20 Song C, Liang L, Jin Y, et al. RCC2 is a novel p53 target in suppressing metastasis. Oncogene 2018;37:8–17.

21 Gong S, Chen Y, Meng F, et al. RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin-resistant ovarian cancer. Faseb J 2019;33:5350–60.

22 McShane LM, Altman DG, Sauerbrei W, et al. Recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180–4.

23 Kulessa LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180–4.

24 Domingo E, Campos C, Kaiaski PJ, et al. Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. Lancet Gastroenterol Hepatol 2018;3:635–43.

25 Frejno M, Zenezini Chiozzi R, Wilhelm M, et al. Pharmacodynamic characterisation of human colon and rectal cancer. Mol Syst Biol 2017;13:951.
26 Smeby J, Sveen A, Merok MA, et al. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. *Ann Oncol* 2018;29:1227–34.

27 Smeby J, Sveen A, Bergsland CH, et al. Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. *ESMO Open* 2019;4:e000523.

28 Punt CJA, Buyse M, Köhne C-H, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. *J Natl Cancer Inst* 2007;99:998–1003.

29 Royston P. Explained variation for survival models. *Stata J* 2006;6:83–96.

30 Gustavsson B, Carlsson G, Machover D, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. *Clin Colorectal Cancer* 2015;14:1–10.

31 Chen Z, Wu W, Huang Y, et al. RCC2 promotes breast cancer progression through regulation of Wnt signaling and inducing EMT. *J Cancer* 2019;10:9837–47.

32 Hamilton PW, Bankhead P, Wang Y, et al. Digital pathology and image analysis in tissue biomarker research. *Methods* 2014;70:59–73.

33 Lopes N, Bergsland CH, Bjørnslett M, et al. Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2. *Lab Invest* 2020;100:120–34.